Finance chief Rawlingson steps down from Arix Bioscience

Biotechnology-focussed venture capital company Arix Bioscience announced the departure of its chief financial officer James Rawlingson on Wednesday.

The London-listed firm also announced the promotion of group financial controller Marcus Karia to group finance director.

It said the changes were taking place with immediate effect.

“On behalf of the board I’d like to thank James for his contribution to Arix in the first stage of our development and wish him well in his future endeavours,” said Arix Bioscience chief executive officer Joe Anderson in a short statement.